Drugs / Autologous Adipose Cells Therapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06869252 | Aug → Nov 2025 overdue | alopecia, skin pigmentation disorder | CERM INC. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Adipose Cells Therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06869252 ↗ |
| Modality | Cell therapy | “Autologous Adipose Cell Therapy seeks to enhance the current autologous fat grafting by isolating early-stage adipose cells from lipoaspirate and optimizing the number of...” NCT06869252 ↗ |